Genentech
A Member of the Roche Group

2026 Independent Medical Education Call for Grants

Issue Date: **August 10, 2026**

The *Independent Medical Education team at Genentech, a member of the Roche Group,* invites accredited educational providers to submit applications for independent, certified medical education grants subject to the terms described below. This Call for Grants (CGN) provides public notice of the availability of funds in a general topic area for activities for which recognized scientific or educational needs exist and funding is available.

Purpose: As part of Genentech's scientific mission, Genentech supports grants for independent medical education that aim to improve patient care by focusing on the improved application of knowledge, competence, and performance among healthcare professionals. This mission is achieved by supporting quality independent education that addresses evidence-based, bona fide educational gaps in accordance with the ACCME, AMA, PhRMA Code, OIG and FDA guidance.

Notification: Genentech CGNs are made available through our online Genentech Funding Request System (gFRS) site (http://funding.gene.com). In addition, an email is distributed to all registered gFRS users who have previously applied for support of an independent education activity. The email distribution list may not always be up to date. Please periodically check our online Genentech Funding Request System (gFRS) site (http://funding.gene.com) to stay informed on current funding priorities. *There have been no predetermined approvals, nor any identified preferred educational providers. All submissions will be reviewed equally and thoroughly.*

Terms and Conditions

1. All grant applications received in response to this CGN will be reviewed in accordance with all Genentech policies and policy guidelines. (Please refer to the publicly available criteria on http://funding.gene.com)
2. This CGN does not commit Genentech to award a grant or pay any costs incurred in the preparation of a response to this request.
3. Genentech reserves the right to approve or deny any or all applications received as a result of this request or to cancel, in part or in its entirety, this CGN.
4. For compliance reasons, and in fairness to all providers, all communications about this CGN must come exclusively to Genentech's department of Medical Education and Research Grants. Failure to comply will automatically disqualify providers.
5. Failure to follow the instructions within this CGN may result in a denial.

Instructions

Eligibility Criteria	• U.S. based education provider • Registered account in gFRS • Accredited to provide CME/CE and in good standing (e.g. ACCME, ANCC, ACPE, etc.)
Geographical Scope	• Educational initiatives must be U.S.-based only

Genentech
A Member of the Roche Group

Submission Directions	Application Process	Deadlines
Step 1	Providers who meet the eligibility criteria and are interested in submitting a response to this CGN are to **complete a full grant proposal** through funding.gene.com by the specified due date. When submitting the application, please be sure to: ● Select the Therapeutic Area (Neuroscience), and Disease State (**Parkinson's Disease**) ● Include **" CGN August 2026 [Insert Program Title]"** in the program title of the grant	September 4, 2026
Step 2	Grant decisions will be made by Genentech and decision notifications will be issued to the accredited educational provider through gFRS.	By September 18, 2026

Additional Considerations

Provider(s) who are awarded grants are encouraged but not required to:

1. Demonstrate key findings via outcomes analysis and report the extent to which the education met the stated objectives and other key findings.
2. Describe how learners demonstrated competence, performance, or improved patient outcomes as a result of the educational activity.
3. Summarize (through written analysis) the provider's understanding and interpretation of the outcomes data and identify any persistent educational gaps, unanticipated barriers and/or activity/outcomes limitations.

Genentech
A Member of the Roche Group

Currently Available CGN Focus Area:

Focus	Opportunity
Therapeutic Area: Neuroscience **Disease Areas:** Parkinson's Disease **Primary Learning Audiences:** Community Neurologists **Support Available:** Up to $150,000	Despite rapid advances in the understanding of alpha-synuclein's role in the pathogenesis of Parkinson's disease (PD), a significant educational gap exists among community neurologists in translating this science into clinical practice.[1] Misfolded alpha-synuclein is now recognized as the central driver of neurodegeneration in PD and the primary target of emerging disease-modifying therapies.[2] In parallel, validated biomarker tools, most notably alpha-synuclein seed amplification assays, now enable biological confirmation of synucleinopathy at earlier disease stages than previously possible, fundamentally reshaping how PD is diagnosed and staged.[3] Yet most community neurologists remain unfamiliar with the biological rationale underpinning these therapies, the evolving clinical trial landscape, and the biomarker testing strategies that will be essential for identifying eligible patients and intervening during the therapeutic windows most likely to yield meaningful benefit.[4] Genentech seeks to educate community neurologists in the role of alpha-synuclein in PD as a target for emerging therapies. **References:** 1. Fields CR, Bengoa-Vergniory N, Wade-Martins R. Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease. Front Mol Neurosci. 2019 Dec 5;12:299. doi: 10.3389/fnmol.2019.00299. 2. Tolosa E, et al. Challenges in the diagnosis of Parkinson's disease. *Lancet Neurology*. 2021;20(5):385–397. doi: 10.1016/S1474-4422(21)00030-2 3. Siderowf A, et al. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study. *Lancet Neurology*. 2023;22(5):407–417. doi: 10.1016/S1474-4422(23)00109-6 4. Espay AJ, et al. Biomarker-driven phenotyping in Parkinson's disease: a translational missing link in disease-modifying clinical trials. Movement Disorders. 2017;32(3):319–324. doi: 10.1002/mds.26913